The pharmaceutical industry is critical to the progress of science in researching, developing and introducing new therapies that improve the health and quality of life for patients around the globe. This continued progress requires an extensive amount of funding and financial risk due to the complexity and unpredictability of basic research, clinical trials and the approval process, which result in many failed drugs for every success. It is estimated that it takes about 10 to 15 years, with an average cost of US$1–2 billion, for each new drug product to be approved for therapeutic use (D Sun, W Gao, H Hu, S Zhou, Why 90% of clinical drug development fails and how to improve it? Acta Pharm Sin B 2022, 12(7):3049–62). Accordingly, exclusivity – provided by a robust patent portfolio and regulatory statutes – is essential in order to recoup the massive investments incurred during research, development and regulatory approval of pharmaceutical products. These exclusivities are also critical in providing and maintaining resources for the further development of other therapies in a company’s pipeline.

Unlike many other industries, the filing and development of a pharmaceutical patent portfolio with the United States Patent and Trademark Office (USPTO) most often occurs concurrently with a long and protracted process before commercialisation can occur. The process includes initial research and development and pre-clinical and clinical trials and culminates with the filing of an application for regulatory approval with the United States Food and Drug Administration (FDA). A US patent expires 20 years from the earliest filing date, not including certain statutorily available extensions. Therefore, it is not uncommon for a patent to be in force and losing valuable patent term while the subject matter of the patent is being developed and under regulatory review. It is also not uncommon that, upon drug approval, the underlying patent has expired or has only a fraction of its available term available.

Click here to view the full article